secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-06-05T20:14:05+00:00
Accession:  0001867096-26-000034
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xeris shareholders elect Halkuff and Johnson as directors; approve auditor and say-on-pay
--------------------------------------------------------------------------------

- Dawn Halkuff elected with 62.6M for, 24.9M withhold; John Johnson with 52.7M for, 34.8M withhold.
- Auditor Ernst & Young ratified for FY2026 with 125.8M for, 1.0M against, 1.4M abstain.
- Advisory say-on-pay approved with 82.2M for, 4.7M against, 0.6M abstain; broker non-votes 40.8M.
- Meeting quorum of 128.3M shares from 172.6M outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/0001867096-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/xers-20260604.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer